Save up -80% on Cobicistat
Note: this is a drug discount program, not an insurance plan.
2018 Price of Cobicistat
* price without discount in nearest pharmacy. Price may vary.
We offer free Cobicistat coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Cobicistat every time. What are you waiting for? Claim your prescription drug card now!
Cobicistat volume of distribution
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Cobicistat
Cobicistat, trade name Tybost (formerly GS-9350), is a licensed drug for use in the treatment of infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
Cobicistat mechanism of action
Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A) isoforms. Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates atazanavir and darunavir and therefore enables increased anti-viral activity at a lower dosage. Cobicistat does not have any anti-HIV activity on its own.
Dosage forms of Cobicistat
|Tablet, film coated||oral|
|Film-coated tablet||Oral use||150 mg|
E.R. Squibb – Sons, L.L.C.
Indication of Cobicistat
Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications.
Toxicity of Cobicistat
The most common adverse reactions reported during clinical trials were jaundice (13%), ocular icterus (15%), and nausea (12%).
RX24 Drugs Disclaimer: before buying a Cobicistat on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.